CD8A and neoplasm: Although our data suggest that [64Cu]NOTA-CD8a could be a suitable in vivo biomarker for response prediction and monitoring of immunotherapy protocols, additional experiments are warranted including different combination strategies, tumor models as well as extending to orthotopic models, as the immune infiltrate and immunotherapeutic efficacy are known to differ with implantation site [36].